Commercial Insight Antithrombotics

Pipeline products to dampen the impact of patent expiries and cost containment initiatives

Publication Date	February 2007
Publisher	Datamonitor
Product Type	Report
Pages	290
ISBN Number	not applicable
Product Code	DAT03306

Price

£8,000.00
approximately: $11,654 | €9,233

PDF

PRINT £8,000 ($11,654 | €9,233)

Order above formats by FAX

Summary

Introduction

The ageing of the population will result in an increased incidence of coronary artery disease, heart failure and stroke. In addition to these epidemiological forces, the antithrombotics market will be sustained by the forthcoming launch of innovative novel agents whose sales revenue is expected to dampen the commercial impact of generic incursion in blockbuster proceeds.

Scope

Country specific event-driven sales forecasts for the period 2006-15 for the US, Japan, France, Germany, Italy, Spain and the UK
Discussion of recent trials and market-shaping future key events
Profiles of the country and market specific issues which will impact future sales in the market including generic erosion and class switching
Case studies evaluating the commercial impact of two developmental agents with blockbuster potential

Highlights

Demographic trends lead to an increase in the patient population requiring antithrombotic therapy. However, the rising age of the population across all developed regions is increasing the fiscal burden on healthcare payors which are likely to respond by limiting the reimbursement potential of therapies and put pricing pressure on all agents.

The highest selling brands in the antidiabetics market are Lovenox (enoxaparin) and Plavix (clopidogrel), but these agents are subject to forthcoming genericization and will thus not contribute to the growth of the antithrombotics market in the medium-to-long term. Pipeline agents are expected to become significant drivers in the market.

The antithrombotics market is characterized by pockets of high unmet need and a broad spectrum of similarly efficacious therapeutic strategies. There is regional bias in the choice and popularity of therapeutic strategies driven by cultural reasons as well as infrastructural confines.

Reasons to Purchase

Quantify future size and scope of the antithrombotics market and potential for new products
Analyze options to expand commercial potential through pursuit of new indications
Formulate successful launch strategies in a highly competitive mature market

Content

Chapter 1 Executive Summary
- Objective of the analysis
- Datamonitor insight into the antithrombotics market
Chapter 2 Market Definition And Overview
- Market definition for this report
- Current market situation
- Antithrombotics market: overview
- Anticoagulants market
- Heparins
- Low molecular weight heparin (LMWH)
- Parenteral non-heparinoid anticoagulants
- Oral anticoagulants
- Antiplatelets market
- ADP receptor antagonists
- cAMP enhancing platelet aggregation inhibitors
- GP 2b/3a inhibitors
- Other antiplatelets
- Thrombolytics market
- National markets
- Anticoagulants
- Antiplatelets
- Thrombolytics
- Key clinical trials
- Key clinical trials in the anticoagulant category
- Lovenox (enoxaparin)
- Angiomax (bivalirudin)
- Arixtra (fondaparinux)
- Key clinical trials in the antiplatelet category
- Plavix (clopidogrel)
- Key clinical trials in the thrombolytics category
- TNK (tenecteplase)
- Actilyse (tPA, alteplase)
Chapter 3 Country Market Assessments
- Current and future opportunities and threats in the antithrombotics market
- Global opportunities and threats
- Opportunity: increasing patient pool due to changes in demography and lifestyle
- Threat: cost-conscious pricing and reimbursement environment
- US
- US opportunities
- US threats
- Japan
- Japan opportunities
- Japan threats
- EU5: opportunities and threats
- EU5 Opportunities
- EU5 Threats
- France: opportunities and threats
- France opportunities
- France threats
- Germany: opportunities and threats
- Germany opportunities
- Germany threats
- Italy: opportunities and threats
- Italy opportunities
- Italy threats
- Spain: opportunities and threats
- Spain opportunities
- Spain threats
- UK: opportunities and threats
- UK opportunities
- UK threats
- Summary of environmental issues affecting the antithrombotic market size
Chapter 4 Forecast Analysis
- Key assumptions and events
- New products
- Future outlook on key marketed products
- Lovenox (enoxaparin)
- Angiomax (bivalirudin)
- Arixtra (fondaparinux)
- Plavix (clopidogrel)
- GP 2b/3a inhibitors and thrombolytics
- Generic incursion: patent expiries and marketing exclusivity
- Limitations of data
- Forecasts
Chapter 5 Case Studies: Key Pipeline Agents
- Case study A - What commercial potential does the oral anticoagulant market segment harbor?
- The market opportunity
- Warfarin's monitoring requirement and dosing complexity generates an opening in the market for novel oral anticoagulants
- Oral antiplatelets are unlikely to threaten commercial potential of emerging oral anticoagulants
- The key competitors in development
- The commercial potential of oral anticoagulants
- Patient potential of oral anticoagulants
- Sales forecast of the two most advanced oral anticoagulants
- Conclusions
- Case study B - Will prasugrel capture the antiplatelet market?
- The market opportunity
- The unmet need profile of the antiplatelet market indicates opportunities for novel antiplatelets.
- Commercial potential of prasugrel
- Drug overview: prasugrel (CS-747)
- Sales forecast of prasugrel
Appendix A
- Bibliography
- Report methodology
- Standard units
- Japanese market data
Appendix B - Market Forecast Data
- US forecasts
- Japan forecasts
- France forecasts
- Germany forecasts
- Italy forecasts
- Spain forecasts
- UK forecasts
- M5EU forecasts
- Global forecasts
- About Datamonitor
- About Datamonitor Healthcare
- About the Cardiovascular Disease analysis team
- Disclaimer